These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 19442214

  • 21. Drugs against avian influenza a virus: design of novel sulfonate inhibitors of neuraminidase N1.
    Udommaneethanakit T, Rungrotmongkol T, Frecer V, Seneci P, Miertus S, Bren U.
    Curr Pharm Des; 2014; 20(21):3478-87. PubMed ID: 24001233
    [Abstract] [Full Text] [Related]

  • 22. Binding mode analysis of anti-influenza drugs in H1N1 (2009) and H5N1 influenza A virus and designing of potential H1N1 inhibitors.
    Singh KhD, Kirubakaran P, Nagamani S, Karthikeyan M.
    Int J Comput Biol Drug Des; 2015; 8(1):1-18. PubMed ID: 25869316
    [Abstract] [Full Text] [Related]

  • 23. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1.
    Malaisree M, Rungrotmongkol T, Decha P, Intharathep P, Aruksakunwong O, Hannongbua S.
    Proteins; 2008 Jun; 71(4):1908-18. PubMed ID: 18175324
    [Abstract] [Full Text] [Related]

  • 24. Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
    Feng E, Ye D, Li J, Zhang D, Wang J, Zhao F, Hilgenfeld R, Zheng M, Jiang H, Liu H.
    ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317
    [Abstract] [Full Text] [Related]

  • 25. Virtual screening pipeline and ligand modelling for H5N1 neuraminidase.
    D'Ursi P, Chiappori F, Merelli I, Cozzi P, Rovida E, Milanesi L.
    Biochem Biophys Res Commun; 2009 Jun 12; 383(4):445-9. PubMed ID: 19371724
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Design, synthesis, and evaluation of carboxyl-modified oseltamivir derivatives with improved lipophilicity as neuraminidase inhibitors.
    Wang B, Wang K, Meng P, Hu Y, Yang F, Liu K, Lei Z, Chen B, Tian Y.
    Bioorg Med Chem Lett; 2018 Nov 15; 28(21):3477-3482. PubMed ID: 30266543
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Mutation-induced loop opening and energetics for binding of tamiflu to influenza N8 neuraminidase.
    Kar P, Knecht V.
    J Phys Chem B; 2012 May 31; 116(21):6137-49. PubMed ID: 22553951
    [Abstract] [Full Text] [Related]

  • 30. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir.
    Park JW, Jo WH.
    J Chem Inf Model; 2009 Dec 31; 49(12):2735-41. PubMed ID: 19957991
    [Abstract] [Full Text] [Related]

  • 31. Comment on 'Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)"'.
    Mitrasinovic PM.
    Biophys Chem; 2011 Mar 31; 154(2-3):102. PubMed ID: 21316835
    [No Abstract] [Full Text] [Related]

  • 32. Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach.
    Mai BK, Li MS.
    Biochem Biophys Res Commun; 2011 Jul 08; 410(3):688-91. PubMed ID: 21693105
    [Abstract] [Full Text] [Related]

  • 33. Selective binding of antiinfluenza drugs and their analogues to 'open' and 'closed' conformations of H5N1 neuraminidase.
    Wang P, Zhang JZ.
    J Phys Chem B; 2010 Oct 14; 114(40):12958-64. PubMed ID: 20860351
    [Abstract] [Full Text] [Related]

  • 34. Discover binding pathways using the sliding binding-box docking approach: application to binding pathways of oseltamivir to avian influenza H5N1 neuraminidase.
    Tran DT, Le LT, Truong TN.
    J Comput Aided Mol Des; 2013 Aug 14; 27(8):689-95. PubMed ID: 23979194
    [Abstract] [Full Text] [Related]

  • 35. Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands.
    Wei DQ, Du QS, Sun H, Chou KC.
    Biochem Biophys Res Commun; 2006 Jun 09; 344(3):1048-55. PubMed ID: 16647045
    [Abstract] [Full Text] [Related]

  • 36. Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.
    Wang K, Lei Z, Zhao L, Chen B, Yang F, Liu K, Zhu H, Zhao H, Cao R, Zhang K, Tian Y.
    Eur J Med Chem; 2020 Jan 01; 185():111841. PubMed ID: 31708183
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Combinatorial design of avian influenza neuraminidase inhibitors containing pyrrolidine core with a reduced susceptibility to viral drug resistance.
    Rungrotmongkol T, Udommaneethanakit T, Frecer V, Miertus S.
    Comb Chem High Throughput Screen; 2010 Mar 01; 13(3):268-77. PubMed ID: 20015013
    [Abstract] [Full Text] [Related]

  • 40. Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
    Pan P, Li L, Li Y, Li D, Hou T.
    Antiviral Res; 2013 Nov 01; 100(2):356-64. PubMed ID: 24055835
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.